Investors
Eyevensys is proud to receive funding from investors committed to helping drive innovation in the health sector. Our investors include:

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical 150 150 Eyevensys

Manufacturing of Eyevensys’ core ocular device and electrical pulse generator technology covered under a new collaboration

Eyevensys Raises $12M in a Series B Plus Funding Round

Eyevensys Raises $12M in a Series B Plus Funding Round 1920 1277 Eyevensys

Paris, France, and Cambridge, Mass., United States, August 04, 2021 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies..

Eyevensys Named to French Tech 120 Program

Eyevensys Named to French Tech 120 Program 1920 1281 Eyevensys

Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…

Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa

Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa 1920 1080 Eyevensys

Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company..